By Professor Alan Fenwick OBE, Director of SCI (Schistosomiasis Control Initiative), Imperial College, London)
A schistosomiasis worm
Schistosomiasis is a type of infection caused by parasites that live in fresh water, such as rivers or lakes, in subtropical and tropical regions worldwide. It is also known as bilharzia.
The Schistosomiasis Control Initiative (SCI) at Imperial College London supports Ministries of Health and Education in 16 countries to deliver medicines to treat people infected with schistosomiasis and three intestinal worms. The medicines are donated by various pharmaceutical companies, Merck KgGA (praziquantel), GSK (albendazle) and Johnson and Johnson (mebendazole), and for the most part, the targets are school aged children.
By Professor Simon Taylor-Robinson and Professor Mark Thursz
Liver cancer is one of the leading causes of mortality worldwide, with an estimated annual mortality rate of 500,000 with a survival rate of less than 5%.
Cirrhosis (scarring of the liver as a result of continuous, long-term liver damage) is the main risk factor for the development of liver cancer in developing countries, such as in West Africa, where viral hepatitis B is the major cause of cirrhosis.
Generally, late presentation of patients with liver cancer results in poor prognosis, due mainly to insufficient and lack of affordable screening tools for early tumour detection.
By Jeremy Laurance
Looked at in one way, the warning from the World Health Organisation of a tidal wave of cancer sweeping the globe over the next 20 years is good news. Cancer is a disease of old age – it means more of the world’s peoples are surviving long enough to get it.
But while it is good to grow old (rather than die young) no one wants to die of cancer. Many cancers still kill people before their time. And cancer imposes an immense and growing burden on families, health systems and states. Hence the WHO’s alarm call.
The organisation estimates the worldwide burden will rise by 70 per cent from 14 million cases in 2012 to 24 million in 2035, much of it borne by poorer countries.
Gabrielle Prager, Winner of IGHI’s 2013 Student Challenges Competition guides us through her journey throughout the contest and the next steps for her research project.
This is the problem: In 2011, 243 million people required treatment for schistosomiasis. 28.1 million were reported to have received that treatment. Schistosomiasis is a neglected tropical disease. What is it? It is a blood dwelling fluke. How is it treated? Mass Drug Administration with Praziquantel has been the mainstay of most treatment programmes. Uganda was the first country in Africa to initiate a national control programme coordinated by the Ministry of Health with technical and financial support from the Schistosomiasis Control Initiative (SCI).
John Chetwood, winner of the 2012 IGHI Student Challenges Competition tells us how he has put the £2000 prize money to good use.
Detecting a Silent Cancer
With the hepatologists at Imperial College London, I had been in rural Thailand investigating urinary biomarkers of ‘cholangiocarcinoma’ or simply put, cancer of the bile ducts. Though cholangiocarcinoma is thankfully rare in developed countries, it is showing worrying increases in incidence, and has shown little improvement in survival over the last 15 years. There is still little hope of cure unless detected early and nearly everyone who develops this cancer will die from it.
Richard Smith of the UnitedHealth Chronic Disease Initiative and Adjunct Professor at IGHI talks about our NCD event at the Royal Society on 4th October and how we can make progress in global health as a whole.
Global health 1.0 was called tropical medicine and was primarily concerned with keeping white men alive in the tropics. Global health 2.0 was called international health and comprised clever people in rich countries doing something to help people in poor countries. It had Cold War overtones. Global health 3.0, which is still the main manifestation of global health, is about researchers from rich countries leading research programmes in poor countries.
Richard Smith of UnitedHealth and Adjunct Professor at IGHI, writes for the BMJ about our upcoming NCD event at the Royal Society on 4th October.
I’m the minister of health in a poor country. Until last year I was a urologist. I was the president’s urologist and took out his prostate. To be honest, I don’t think it needed to come out, but he insisted. You don’t resist the president. He was delighted with the result and rewarded me by making me minister of health.
It doesn’t feel like a reward. Everybody wants something from me, but I’m very low in the hierarchy.
The 5th July marked the 65th anniversary of the NHS. To mark the occasion, the Nuffield Trust has published a new report ‘Wisdom of the Crowd: 65 views of the NHS at 65’ which invites 65 health and political leaders to give their opinion on the current state of the NHS and social care system. They have been asked specifically to reflect on what they think needs to happen now and over the coming years to ensure the NHS and social care system is viable and fit for purpose in ten years’ time.
Professor Lord Ara Darzi, Director of the Institute of Global Health Innovation
Contributors consisted of current and former health secretaries and ministers, senior civil servants, clinicians, managers, academics, patient representatives, journalists and other key individuals.
Welcome to the blog pages of the Institute of Global Health Innovation, Imperial College London.
This site provides frequent blog posts from staff and students within the College relating to the various global health topics we are working on within the institute and Imperial. It aims to be an arena for debate and discussion and we welcome your comments and suggestions.
We are always looking for guest bloggers (internal and external to the College). If you would like to write for our blog, contact IGHI’s Communications Manager, Jo Seed firstname.lastname@example.org tel 0207 594 1484